AnaptysBio, Inc. filed an 8-K on August 11, 2026, reporting the voting outcomes from its 2026 Annual Meeting of Stockholders held that same day on four separate proposals.

Key Highlights

  • Two directors elected: Hollings Renton and John P. Schmid were each elected as Class III directors to serve three-year terms expiring at the 2029 Annual Meeting.
  • Renton vote totals: 15,304,522 shares voted for, 6,613,642 withheld or abstaining, and 2,084,465 broker non-votes.
  • Schmid vote totals: 20,314,669 shares voted for, 1,603,495 withheld or abstaining, and 2,084,465 broker non-votes.
  • Auditor ratified: KPMG LLP was ratified as independent registered public accounting firm for the fiscal year ending June 30, 2027, with 22,343,352 shares in favor.
  • Executive pay approved: The non-binding advisory say-on-pay vote passed with 21,274,791 shares for and 609,979 against.
  • Equity plan amended: The amendment to the 2017 Equity Incentive Plan was approved with 15,563,882 shares for and 6,332,813 against.

AnaptysBio Stockholders Vote on Directors, Auditor, Pay, and Equity Plan

According to the filing, AnaptysBio, Inc. (NASDAQ:ANAB) held its 2026 Annual Meeting of Stockholders on August 11, 2026. Four proposals were presented to stockholders, and all four were adopted. The company is incorporated in Delaware and headquartered at 10770 Wateridge Circle, Suite 210, San Diego, California 92121.

On the director election, the filing reported that Hollings Renton received 15,304,522 shares for his election compared to 6,613,642 shares withheld or abstaining, while John P. Schmid received 20,314,669 shares for and 1,603,495 withheld or abstaining. Both candidates carry 2,084,465 broker non-votes. Each director will serve until the 2029 Annual Meeting of Stockholders, or until a successor is duly elected and qualified, or until earlier resignation or removal, as the filing states.

The ratification of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending June 30, 2027, received 22,343,352 shares in favor, 1,640,401 against, and 18,876 withheld or abstaining, with no broker non-votes recorded for that proposal. The non-binding advisory compensation vote garnered 21,274,791 shares for, 609,979 against, and 33,394 abstaining, with 2,084,465 broker non-votes. The amendment to the Company's 2017 Equity Incentive Plan received 15,563,882 votes for and 6,332,813 against, with 21,469 abstaining and 2,084,465 broker non-votes. The filing lists Amendment No. 1 to the Amended and Restated 2017 Equity Incentive Plan as Exhibit 10.1. The 8-K was signed by Christopher M. Murphy, Chief Financial Officer.

What Was Disclosed

AnaptysBio disclosed the stockholder vote tallies from its August 11, 2026 Annual Meeting covering director elections, auditor ratification, executive compensation advisory approval, and an equity incentive plan amendment, all of which were adopted.